Literature DB >> 18784985

Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients.

Alper Kepez1, Ayla Harmanci, Tuncay Hazirolan, Mehlika Isildak, Ugur Kocabas, Ahmet Ates, Orcun Ciftci, Lale Tokgozoglu, Alper Gürlek.   

Abstract

OBJECTIVE: Although there is sufficient data supporting the increased cardiovascular risk in patients with advanced stage of primary hyperparathyroidism (pHPT), it is not clear whether same is valid for patients with subclinical forms of this disease. In this study we aimed to evaluate coronary atherosclerosis burden of asymptomatic pHPT patients by using tomographic coronary calcification scoring. PATIENTS AND METHODS: Thirty-one mild asymptomatic pHPT patients (28 female, 3 male; mean age: 54.4 +/- 12.1 years) and 19 gender- and age-matched normotensive healthy controls (17 female, 2 male; mean age: 50.6 +/- 5.8) constituted our study population. Asymptomatic pHPT patients were subdivided according to presence of hypertension (19 hypertensive and 12 non-hypertensive patients). All subjects in study population underwent tomographic coronary calcification scoring by using 16-multidetector computed tomography (16-MDCT).
RESULTS: Median tomographic coronary calcification score was comparable between the whole group of pHPT patients [0.0 (Interquartile Range, IQR:18.70] and the controls [0.0 (IQR: 0.90). Median tomographic coronary calcification scores of pHPT patients with hypertension was 0.90 (IQR: 75.0) HU, whereas no calcification was noted in coronary arteries of normotensive pHPT patients. Calcification scores of hypertensive pHPT patients were significantly higher than both normotensive pHPT patients (P = 0.014) and controls (P = 0.046). There was no significant difference regarding calcification scores of normotensive pHPT patients versus controls. In the binary logistic regression model, only the presence of hyperlipidemia was found to be independently associated with presence of calcification on coronary arteries (relative risk 6.56, 95% CI 1.18-36.56, P = 0.032).
CONCLUSION: These results suggest that mild asymptomatic pHPT with serum calcium levels in the high-normal range does not constitute an independent risk factor for coronary atherosclerosis. The combined presence of classic cardiovascular risk factors determines the severity of coronary atherosclerosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784985     DOI: 10.1007/s10554-008-9369-2

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  25 in total

1.  Editorial: cardiovascular disease in primary hyperparathyroidism.

Authors:  S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

2.  Active serum vitamin D levels are inversely correlated with coronary calcification.

Authors:  K E Watson; M L Abrolat; L L Malone; J M Hoeg; T Doherty; R Detrano; L L Demer
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

3.  Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy.

Authors:  I L Nilsson; J Aberg; J Rastad; L Lind
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

4.  Arterial stiffness in mild primary hyperparathyroidism.

Authors:  Mishaela R Rubin; Mathew S Maurer; Donald J McMahon; John P Bilezikian; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

5.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

6.  Serum calcium and survival in a large health screening program.

Authors:  B G Leifsson; B Ahrén
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

7.  Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism.

Authors:  Christina Gerlach Ogard; Mads D Engelmann; Caroline Kistorp; Steen Levin Nielsen; Henrik Vestergaard
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

8.  Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979.

Authors:  M Palmér; H O Adami; R Bergström; G Akerström; S Ljunghall
Journal:  Surgery       Date:  1987-07       Impact factor: 3.982

Review 9.  Parathyroid adenomas and cardiovascular risk.

Authors:  N Garcia de la Torre; J A H Wass; H E Turner
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

10.  Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study.

Authors:  Elena Kamycheva; Johan Sundsfjord; Rolf Jorde
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2004-02
View more
  4 in total

1.  Evaluation of left ventricular functions in patients with primary hyperparathyroidism: is there any effect of parathyroidectomy?

Authors:  Alper Kepez; Mehmet Yasar; Murat Sunbul; Cigdem Ileri; Oguzhan Deyneli; Bulent Mutlu; Osman Yesildag; Yelda Basaran
Journal:  Wien Klin Wochenschr       Date:  2017-03-17       Impact factor: 1.704

2.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

Review 3.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

4.  Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism.

Authors:  Patrícia Nunes Mesquita; Ana Paula Dornelas Leão Leite; Stella das Chagas Crisóstomo; Enio Veras Filho; Lucas da Cunha Xavier; Francisco Bandeira
Journal:  Vasc Health Risk Manag       Date:  2017-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.